Nektar Therapeutics stated during its Q2 earnings call on August 13 that its lead candidate, rezpegaldesleukin (rezpeg), is undergoing two Phase III clinical trials for autoimmune diseases. Despite the company's Q2 operating loss widening to $42.3 million, its cash reserves of $1.02 billion are expected to support operations until 2028. The company anticipates full-year R&D expenditures to be between $210 million and $230 million, with key clinical trial data expected in mid-2028 and a Biologics License Application (BLA) planned for submission in 2029. Additionally, the company faces a federal court jury trial on September 8, 2026.